UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13D

                    Under the Securities Exchange Act of 1934
                               (Amendment No. 6)*

                                  LABONE, INC.
                                (Name of Issuer)

                           Common Stock $.01 Par Value
                         (Title of Class of Securities)

                                  505 40 E 101
                                 (CUSIP Number)

                 John H. Calvert, 2345 Grand Blvd., Suite 2800,
                      Kansas City, MO 64108, (816) 460-5807
                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)

                                    03/07/99
             (Date of Event which Requires Filing of this Statement)

If the  reporting  person has  previously  filed a statement  on Schedule 13G to
report the acquisition  which is the subject of this Schedule 13D, and is filing
this  schedule  because of Rule 13d-1(b) (3) or (4),  check the  following  box.
______

Check the  following box if a fee is being paid with this  statement.  ______ (A
fee is not required only if the reporting person:  (1) has a previous  statement
on file reporting beneficial ownership of more than five percent of the class of
securities  described  in Item 1;  and (2) has  filed  no  amendment  subsequent
thereto reporting  beneficial  ownership of five percent or less of such class.)
(See Rule 13d-7).

Note:  Six copies of this statement, including all  exhibits,  should  be  filed
with the Commission.  See Rule 13d-1 (a) for other parties to whom copies are to
be sent.
- ---------------------
*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for any  subsequent  amendment  containing  information  which  would  alter the
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).

                               Page 1 of 9 Pages








(1)     Name of Reporting Person
          S.S. or I.R.S. Identification No. of Above Person

          Lab Holdings, Inc.
          43-1039532

(2)     Check the Appropriate Box                       (a)   ______
          if a Member of a Group*                       (b)   ______

(3)     SEC Use Only

(4)     Source of funds*
          WC, BK

(5)     Check Box if Disclosure of Legal Proceedings is
          Required Pursuant to Items 2(d) or 2(e)                      ______

(6)     Citizenship or Place of Organization
           Missouri

           Number of Shares        (7)     Sole Voting Power
           beneficially Owned                10,712,200
           by Each Reporting       (8)     Shared Voting Power
           Person With                          -0-
                                   (9)     Sole Dispositive Power
                                             10,712,200
                                   (10)    Shared Dispositive Power
                                                -0-

(11)     Aggregate Amount Beneficially Owned By Each Reporting Person
            10,712,200

(12)     Check Box if the Aggregate Amount in Row (11) Excludes Certain 
             Shares*                                                   ______

(13)     Percent of Class Represented by Amount in  Row (11)
         80.5%

(14)     Type of Reporting Person*
                         CO, HC

*  See Instructions before Filling Out!



                                Page 2 of 9 Pages







Item 1.      Security and Issuer.

           This Amendment No. 6 ("Amendment No. 6") to Schedule 13D concerns the
common stock  par  value  $.01  per  share  ("Common  Stock")  of  LabOne,  Inc.
("LabOne") whose principal  executive offices are at 10101 Renner Blvd., Lenexa,
Kansas 66219.  Amendment No. 6 amends an original report (the "Original Report")
on  Schedule  13D  filed  November  29,  1990  respecting Home Office  Reference
Laboratory, Inc., the former name of LabOne, as such Original  Report  has  been
amended by Amendment No. 1 to Schedule 13D, dated January 28,  1991  ("Amendment
No. 1"), Amendment No. 2 to Schedule 13D, dated February  17,  1992  ("Amendment
No. 2"), Amendment No. 3 to Schedule 13D, dated December 2, 1993 ("Amendment No.
3"),  Amendment  No. 4 to Schedule 13 D, dated February 21, 1995 ("Amendment No.
4"), and  Amendment No. 5 to Schedule 13D dated July 1, 1997 ("Amendment No. 5")
(collectively, Amendments  No.  1,  No.  2, No. 3, No. 4 and No. 5 are sometimes
referred to as the "Prior Amendments").

Item 2.    Identity and Background.

           This report is filed by Lab Holdings,  Inc. ("the Company") (formerly
named Seafield Capital  Corporation,  which was formerly named BMA Corporation).
The Company is a Missouri  corporation.  The address of its principal  executive
office is 5000 West 95th  Street,  Suite 260,  P.O. Box 7568,  Shawnee  Mission,
Kansas 66207.  The Company is a holding company whose principal  business is the
management  of its  investment in LabOne.  LabOne  provides  laboratory  testing
services on a world-wide basis for insurance risk appraisal, clinical use in the
health care industry and employee screening for substance abuse.

         The Company and LabOne  entered  into an  Agreement  and Plan of Merger
dated March 7, 1999 ("Merger  Agreement").  A copy of the Merger Agreement and a
description  of the terms of the merger are contained in the Company's  Form 8-K
dated March 7, 1999, which information is incorporated  herein by reference (the
"Form 8-K").

         Set forth in Schedule 1 hereto are the names,  business  addresses  and
principal  occupations or employment of the executive  officers and directors of
the Company. Each person listed on Schedule 1 is a United States citizen.

         During the past five years,  neither the Company, nor to its knowledge,
any of the persons identified in Schedule 1 has been (i) convicted in a criminal
proceeding,   or  (ii)  a  party  to  a  civil   proceeding  of  a  judicial  or
administrative  body as a result of which  such  person  was or is  subject to a
judgment,  decree or final order enjoining future  violations of, or prohibiting
or mandating  activities subject to, federal or state securities laws or finding
any violation with respect to such laws.

Item 3.     Source and Amount of Funds or Other Consideration.

         Stockholders  of the Company will have their Lab Holdings  shares split
immediately before the merger into 1.50 shares of the survivor.  Stockholders of
LabOne, other than the

                                Page 3 of 9 Pages







Company,  will be entitled to elect to have each of their existing LabOne shares
exchanged  for one share of the survivor or $12.75 in cash or a  combination  of
cash and shares.  However,  if the cash  election  shares exceed a cash limit of
$16.6  million  (approximately  50% of  eligible  shares)  then the cash will be
allocated  on a pro rata  basis  among  the cash  election  shares.  The  Merger
Agreement  is  conditional  upon the Company  obtaining  necessary  financing to
satisfy cash  elections.  The sources and amounts of funds  necessary to satisfy
the $16.6 million cash maximum  include:  (i) available cash held by the Company
and LabOne;  and (ii)  financing  to be obtained by the Company of the  balance.
Arrangements for obtaining the requisite financing have not been completed.

Item 4.     Purpose of the Transaction.

         The  Company  has  entered  into the Merger  Agreement  for a number of
reasons,  the  principal  ones of  which  are set  forth  in the Form 8-K and as
follows:

         *        LabOne is the Company's  only  remaining  material asset other
                  than   cash,   and  the  Merger   will  allow  the   Company's
                  stockholders to hold their equity interests in LabOne directly
                  rather   than   indirectly   through  the   Company,   thereby
                  eliminating  holding  company  management  and  administrative
                  costs;

         *        The merger will facilitate the use by LabOne of its stock as a
                  currency  in  creating  strategic  relationships with business
                  partners;

         *        The merger will position  LabOne to grow both  internally  and
                  through   acquisition,   and  will   enable  it  to   consider
                  transactions not feasible in the existing structure;

         *        The merger should enable LabOne to effect pooling-of-interests
                  transactions;

         *        By  consolidating   management,   the   merger   will  sharpen
                  management and investor focus;

         *        The  merger  should  increase  LabOne's  float  and  turnover,
                  thereby  creating the  opportunity  for increased  Wall Street
                  research coverage and investor interest;

         *        The merger also comes at the right time since LabOne is now in
                  the  process  of moving  into new and larger  facilities  that
                  provide  it with the  ability  to  handle  larger  volumes  of
                  testing services.

         Under the merger  agreement LabOne is to be merged into the Company but
the survivor's name will be changed to "LabOne, Inc." Management of the survivor
will consist of the present  LabOne  management  and the  survivor's  board will
consist of nine of the present eleven member LabOne Board.  Two new  independent
directors  selected by the Company the Special Committee referred to in the Form
8-K will  replace two  positions  now held by members of  management,  so that a
majority of the board will consist of independent directors.


                                Page 4 of 9 Pages







At the effective  time of the merger it is also  anticipated  that an additional
director  will be added to the board of the  survivor  who will have  experience
with regard to LabOne's  clinical  testing  services.  Following  the merger the
dividend policy of the survivor will be decided by the new board of directors of
the survivor.

         At the  effective  time of the merger the present  corporate  officers,
directors  and  employees  of the  Company as listed on Schedule 1 will cease to
continue  in  those  offices  and  will  hold no  positions,  offices  or  other
employments with the survivor; provided that W. Thomas Grant II, the Chairman of
the Board,  President and Chief  Executive  Officer of LabOne,  who is listed on
Schedule 1, will be the  Chairman of the Board,  President  and Chief  Executive
Officer of the survivor.

         The effect of the merger will be to cause the common stock of LabOne, a
Delaware  corporation,  to no longer be quoted on the National  Market System of
the  NASDAQ  Stock  Market  or to be  registered  under  Section  12(g)  of  the
Securities  Exchange  Act of 1934.  However,  the name,  par value and number of
authorized shares of Common Stock of the Company, as the surviving company, will
be changed to that of LabOne.  Accordingly,  it is expected  that the  surviving
company's shares will continue to be traded on the National Market System of the
NASDAQ Stock Market under the name of "LabOne,  Inc." and under the LABS trading
symbol.

         The  Company  expects  to  file  a  registration  statement  under  the
Securities Act of 1933 to effect the merger and such  registration  statement is
expected to provide additional information relating to the proposed merger.

         Except as noted  above,  or as  provided in the Merger  Agreement,  the
Company has no plans  which may relate to or would  result in any of the effects
specified in Item 4 of Schedule 13D.

         Item 5.     Interest in Securities of the Issuer.

           (a), (b) and (c)

         At present and as  previously  reported in the Original  Report and the
Prior  Amendments,  the Company  beneficially  owns 10,712,200  shares of LabOne
Common  Stock.  The  Company  has sole power to vote and  dispose of all of such
shares. The Company acquired all of said shares for investment purposes.

         The  number of shares  beneficially  owned by the  Company  constitutes
approximately  80.5%  of  LabOne's  Outstanding  Common  Stock,   calculated  in
accordance with Exchange Act Rule 13d-3(d)(1).  This percentage does not reflect
shares  subject to issue upon exercise of stock  options and warrants  presently
outstanding and owned by persons other than the Company.





                                Page 5 of 9 Pages







           Certain of the  persons  named in Schedule 1 are known by the Company
to beneficially  own shares of LabOne Common Stock.  To the Company's  knowledge
these shares were acquired by such persons  solely for  investment  purposes and
such  persons  have sole power to vote and dispose of such  shares.  The Company
disclaims any beneficial  ownership in any of such shares.  The persons known to
the  Company to  beneficially  own such  shares  and the  number of such  shares
beneficially owned by such persons (with an indication of the shares which there
is a right to acquire) are as follows:

             Name                                      Number of Shares

       W. Thomas Grant II                                  81,596*
       Steven K. Fitzwater                                      5
      ---------------------
                  *        Includes  57,431 shares subject to outstanding  stock
                           options   which   are   presently    exercisable   or
                           exercisable within 60 days.

         No  transaction  in shares of LabOne Common Stock were effected  during
the past 60 days by the Company or, to its  knowledge,  any of the persons named
in Schedule 1.

         (d) and (e)     Not Applicable.

Item 6.     Contracts, Arrangements, Understanding or Relationships with Respect
to Securities of the Issuer.

         None, other than as set forth in the Merger  Agreement  attached to the
Form 8-K and incorporated by reference herein.

Item 7.     Exhibits.

         99.1     Agreement and Plan of Merger dated March 7, 1999 (Incorporated
                  by reference  from Exhibit 2 to the  Company's  Form 8-K filed
                  March 8, 1999).















                                Page 6 of 9 Pages







                                    SIGNATURE

         After reasonable  inquiry and to the best of my knowledge and belief, I
certify that the information  set forth in this statement is true,  complete and
correct.


         LAB HOLDINGS, INC.


         By: /s/ Steven K. Fitzwater
             Steven K. Fitzwater, Executive Vice President
             Chief Operating and Financial Officer and
             Secretary


         Date:    March 11, 1999






























                                Page 7 of 9 Pages







                                   SCHEDULE 1

         Directors of Lab Holdings, Inc.

         Name, Occupation and Business Address

Lan C. Bentsen
Executive Vice President of Frontera Resources (Oil & Gas)
3040 Post Oak Boulevard, Suite 730
Houston, Texas  77056

P. Anthony Jacobs, President and Chief Executive Officer
Lab Holdings, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

John H. Robinson, Jr., Managing Partner
Black & Veatch (design and construction)
11401 Lamar Avenue
Overland Park, Kansas  66211-1598

Steven K. Fitzwater, Executive Vice President,
Chief Operating and Financial Officer and Secretary
Lab Holdings, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207


          Executive Officers of Lab Holdings, Inc.

           Name,  Position and Business Address


P. Anthony Jacobs, President and Chief Executive Officer
Lab Holdings, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Steven K. Fitzwater, Executive Vice President, 
Chief Operating  and Financial Officer and Secretary
Lab Holdings, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207



                                Page 8 of 9 Pages









Linda McCoy, Vice President, Chief Accounting Officer
Lab Holdings, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

W. Thomas Grant II, Chairman of the Board,
President and Chief Executive Officer of LabOne, Inc.1
10310 West 84th Terrace
Lenexa, Kansas 66214

























- --------
  1 LabOne, Inc. is 80.5% owned by the Company. Effective February 13, 1998, the
Company's  board of  directors  designated  W. Thomas  Grant II as an  Executive
Officer of the Company  because  LabOne was determined to constitute a principal
business  unit of the  Company.  Mr.  Grant  became the  Chairman  of the Board,
President and Chief  Executive  Officer of LabOne in October 1995.  Mr. Grant is
not a corporate  officer of the Company.  He was Chairman of the Board and Chief
Executive  Officer of the Company from May 1993 to September  1997.  He had been
President and Chief Executive Officer of the Company since 1986.

                                Page 9 of 9 Pages









                                            EXHIBIT INDEX


         99.1     Agreement and Plan of Merger dated March 7, 1999 (Incorporated
                  by reference  from Exhibit 2 to the  Company's  Form 8-K filed
                  March 8, 1999).